BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
0.9993
-0.3507 (-25.98%)
At close: Aug 7, 2026, 4:00 PM EDT
1.005
+0.006 (0.57%)
Pre-market: Aug 10, 2026, 9:07 AM EDT
Company Description
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.
It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program.
The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
BioVie Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Cuong Viet Do |
Contact Details
Address: 680 W. Nye Lane, Suite 204 Carson City, Nevada 89703 United States | |
| Phone | 775 888 3162 |
| Website | bioviepharma.com |
Stock Details
| Ticker Symbol | BIVI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 1580149 |
| CUSIP Number | 09074F504 |
| ISIN Number | US09074F5044 |
| Employer ID | 46-2510769 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cuong Viet Do M.B.A. | President, Chief Executive Officer and Director |
| Dr. Joseph M. Palumbo M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| Clarence N. Ahlem | Senior Vice President of Operations |
| Denise Smith | Senior Vice President of Manufacturing and Development |
| Dr. Christopher L. Reading Ph.D. | Senior Vice President of Alzheimer's Disease Program |
| David Morse | Senior Vice President and Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2026 | SCHEDULE 13G/A | Filing |
| Aug 7, 2026 | SCHEDULE 13G | Filing |
| Aug 7, 2026 | FWP | Free Writing Prospectus |
| Aug 6, 2026 | FWP | Free Writing Prospectus |
| Aug 6, 2026 | FWP | Free Writing Prospectus |
| Aug 6, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 31, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 17, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 29, 2026 | EFFECT | Notice of Effectiveness |